AbbVie Inc (ABBV)vsLivaNova PLC (LIVN)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
LIVN
LivaNova PLC
$78.18
0.00%
HEALTHCARE · Cap: $4.50B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4275% more annual revenue ($64.39B vs $1.47B). LIVN leads profitability with a 12.8% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
LIVN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+7.7%
Fair Value
$71.98
Current Price
$78.18
$6.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 287.8% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : LIVN
The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : LIVN
The primary concerns for LIVN are Altman Z-Score.
Key Dynamics to Monitor
LIVN carries more volatility with a beta of 0.87 — expect wider price swings.
LIVN is growing revenue faster at 10.8% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 68/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?